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GUEST EDITORIAL 
Coming soon: austerity in healthcare. 
During the “Great Recession” of 
recent years, those of us employed in 
healthcare have largely avoided the tumult 
experienced in other sectors, like housing 
and finance. Jobs have actually been 
added to the healthcare sector, payments 
for healthcare services have remained 
stable enough to sustain the system, and 
new opportunity presents itself with more 
Americans likely to obtain coverage as a 
result of the Affordable Care Act (ACA). 
Let’s face it, we’ve been quite fortunate.
However, from a budgetary standpoint, 
we face unprecedented challenges. The 
fiscal cliff legislation, passed at the 11th 
hour on January 1, preserves payments 
to physicians but cuts payments for end-
stage renal disease (estimated savings 
$4.9 billion), resets the base for certain 
types of Medicaid payments to hospitals 
(estimated savings $4.2 billion), and 
recoups past overpayments to hospitals 
through documentation and coding 
adjustments (estimated savings $10.5 
billion). Additional healthcare spending 
reductions are likely in coming months 
when Congress renews its battle over 
increasing the debt ceiling, and tradeoffs in 
the form of more spending cuts are already 
part of the political discussion.
The addition of newly-covered patients 
under ACA, coupled with these budgetary 
challenges, means the system will have 
to provide more care for less money. 
Meanwhile, the overhead cost of simply 
“doing business”—compliance with 
regulations, performance measures, and 
accreditation standards—seems to be 
going up. As someone who has grown 
accustomed to stability, these changes 
are fast, furious, and frightening. What 
will be the key to our success in this new 
era of healthcare? I’ve thought about this 
and keep coming back to the same word: 
efficiency. Never has there been a greater 
need to understand how to best spend our 
healthcare dollars. We need to recognize 
what are the most resource intensive 
components of care, and determine 
whether there are ways to deliver those 
components more cheaply or quickly—all 
while maintaining our shared priority of 
excellence in patient care.
As an applied health economics researcher 
for 15 years, I’m seeing the “efficiency” 
theme play out every day in my work.  The 
overall demand for cost data is increasing, 
but the nature of the questions to be 
answered by these data is changing. A 
decade ago, a common question was: “Is  
the treatment cost effective?”  Now, the 
usual questions are: “What will it cost to 
implement this treatment?”,  “How can the 
treatment be implemented most efficiently?” 
and “What will be the return on investment 
if we implement this treatment?” In other 
words, the conversation is shifting away 
from a willingness to accept increased costs 
for treatments that are more effective, and 
towards purely budget-based and operational 
decision making aimed at determining 
how to do things more affordably. From 
a scientific perspective, this shift suggests 
that cost-benefit analyses will emerge as 
the most relevant type of cost analysis 
(the goal being to determine whether 
investment in a treatment results in net 
financial benefits, i.e., savings, elsewhere in 
the system), with the more traditional cost-
effectiveness analyses (where one considers 
the incremental cost per incremental health 
benefit compared to the standard of care) 
potentially falling out of favor.
Consider, for example, a key area of 
pharmaceutical innovation -- the new oral 
anticoagulants dabigatran, rivaroxaban 
and apixaban. While real-world evidence 
on the effectiveness and safety of these 
drugs is still emerging, from an economic 
standpoint the key question is whether 
the higher price of these drugs is offset 
by measurable efficiencies in the form 
of reduced patient monitoring and 
counseling requirements when compared 
to warfarin. Next, consider improved 
testing for diagnosis and staging of 
prostate cancer.  Here the question is also 
whether the additional costs of the test 
are offset by more efficiently targeting 
men who need treatment, and avoiding 
unnecessary treatment in men who are 
unlikely to benefit. Finally, consider patient 
support programs for seniors with mild-
to-moderate dementia. Again, the key 
question is whether investment in coaching 
the patient and their family caregivers 
-- perhaps even making infrastructural 
improvements to the home -- could delay 
formal paid caregiving and admission to 
long-term care. Just start looking around 
at the innovations being considered in 
your area of healthcare and you will notice 
this shift which now spans across drugs, 
devices, diagnostic assays, and patient 
support programs.
Members of the healthcare community, we 
need to collectively acknowledge this new 
reality and embrace it because, short of a 
miraculous economic recovery, healthcare 
budget cutting will present very difficult 
challenges. It may be politically unpopular 
for the government to formally support or 
mandate cost analyses, but we desperately 
need these data in order to understand how 
to treat patients most efficiently. Those of 
us in the trenches can and will be doing this 
work—we no longer have a choice. I hope 
you will join me in supporting it as a key 
component of the critical real-world evidence 
necessary to inform healthcare decisions. 
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